Evidence map›Paper›PMID 29651712›Full record

ArticleLa Radiologia medica2018

Prognostic impact of nodal relapse in definitive prostate-only irradiation.

Mauro Loi, Luca Incrocci, Isacco Desideri, Pierluigi Bonomo, Beatrice Detti, Gabriele Simontacchi, Daniela Greto, Emanuela Olmetto, Giulio Francolini, Icro Meattini and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in La Radiologia medica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Mauro LoiRadiation Oncology Unit, University of Florence, L.go brambilla 3, Florence, Italy. mauro.loi82@gmail.com.ORCID http://orcid.org/0000-0002-0360-3275
Luca IncrocciRadiotherapy Department, Erasmus MC Hospital, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands.
Isacco DesideriRadiation Oncology Unit, University of Florence, L.go brambilla 3, Florence, Italy.
Pierluigi BonomoRadiation Oncology Unit, University of Florence, L.go brambilla 3, Florence, Italy.
Beatrice DettiRadiation Oncology Unit, University of Florence, L.go brambilla 3, Florence, Italy.
Gabriele SimontacchiRadiation Oncology Unit, University of Florence, L.go brambilla 3, Florence, Italy.
Daniela GretoRadiation Oncology Unit, University of Florence, L.go brambilla 3, Florence, Italy.
Emanuela OlmettoRadiation Oncology Unit, University of Florence, L.go brambilla 3, Florence, Italy.
Giulio FrancoliniRadiation Oncology Unit, University of Florence, L.go brambilla 3, Florence, Italy.
Icro MeattiniRadiation Oncology Unit, University of Florence, L.go brambilla 3, Florence, Italy.
Lorenzo LiviRadiation Oncology Unit, University of Florence, L.go brambilla 3, Florence, Italy.
University of Florence · ITErasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhole pelvic irradiation in prostate cancer patients might prevent metastatic spread of cancer cells through lymphatic drainages in patients eligible for definitive radiotherapy, but its use has declined in the last decades in favor of prostate-only irradiation (POI). The aim of our study is to assess the incidence of pelvic lymph nodal relapse and outcome in prostate cancer patients receiving POI. MATERIALS AND

methodsData from 207 consecutive patients were collected. Clinical and treatment variables were collected. Biochemical relapse-free survival (BRFS), pelvic nodal relapse-free survival (PNRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS) and overall survival (OS) were calculated; analysis of prognostic variables was performed.

resultsFive-year BRFS, PNRFS, DMFS, DSS and OS were, respectively, 90, 98, 96, 97 and 91%. On multivariate analysis, independent negative predictors of BRFS were Gleason score ≥ 7 (HR: 3.25) and PSA nadir ≥ 0.08 (HR: 4.86). Pelvic nodal relapse was not correlated to impaired outcome.

conclusionsLymph nodal pelvic relapse occurs in 2% of patients at 5 years and does not correlate with impaired outcome, suggesting the lack of theoretical benefit of a prophylactic nodal irradiation. Tumor biology and response to treatment are the main determinants of outcome.

Indexed as

AdenocarcinomaAgedAged, 80 and overHumansImage-Guided BiopsyLymphatic MetastasisMaleMiddle AgedPrognosisProstate-Specific AntigenProstatic NeoplasmsRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedRetrospective StudiesSurvival RateTreatment OutcomeProstate-Specific AntigenDefinitive radiotherapyProstate cancerProstate-only irradiationWhole pelvic irradiation

Identifiers

PMID29651712
OpenAlexW2800999308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.